Clopidogrel – current recommendations Review article
Article Sidebar
Published:
Jun 30, 2010
Keywords:
clopidogrel, acetylsalicylic acid, antiplatelet treatment, acute coronary syndrome
Main Article Content
Abstract
Current recommendations for clopidogrel treatment. In this paper was described trials which showed effective use of clopidogrel for prevention of atherosclerosis complications like acute coronary syndrome, stroke and cardiovascular death.
Downloads
Download data is not yet available.
Article Details
How to Cite
Artyszuk , Łukasz. (2010). Clopidogrel – current recommendations. Cardiology in Practice, 4(2), 70-73. Retrieved from https://journalsmededu.pl/index.php/kwp/article/view/1637
Issue
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Savi P., Zachayus J.L., Delesque-Touchard N., Labouret C., Hervé C., Uzabiaga M.F., Pereillo J.M., Culouscou J.M., Bono F., Ferrara P., Herbert J.M.: The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc. Natl. Acad. Sci. USA 2006 Jul 18, 103(29): 11069-74.
2. Katzung B.: Basic and clinical pharmacology. 10th edition. McGraw Hill, 2007.
3. von Beckerath N., Taubert D., Pogatsa-Murray G., Schomig E., Kastrati A., Schomig A.: Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 2005, 112: 2946-2950.
4. Antman E.M., Hand M., Armstrong P.W. et al.: 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. Circulation 2008, 117: 296-329.
5. Bassand J.P., Hamm C.W., Ardissino D. et al.: Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur. Heart J. 2007, 28: 1598-1660.
6. King S.B., Smith S.C., Hirshfeld J.W. et al.: 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J. Am. Coll. Cardiol. 2008, 51: 172-209.
7. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348: 1329-39.
8. Bhatt D.L., Topol E.J.; Clopidogrel for High Atherothrombotic Risk and ischemic Stabilization, Management, and Avoidance Executive Committee: Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am. Heart J. 2004 Aug, 148(2): 263-8.
9. CURE trial investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 2001, 345: 494-502.
10. Steinhubl S.R., Berger P.B., Mann J.T. III et al. (for the CREDO Investigators): Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002, 288: 2411-20.
11. Mehta S.R., Yusuf S., Peters R.J. et al.: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001, 358: 527-533.
12. Patti G., Colonna G., Pasceri V., Pepe L.L., Montinaro A., Di Sciascio G.: Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005 Apr 26, 111(16): 2099-106.
13. Sabatine M.S., Cannon C.P., Gibson C.M. et al. (for the CLARITY-TIMI 28 Investigators): Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med. 2005, 352: 1179-89.
14. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group: Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebocontrolled trial. Lancet 2005, 366: 1607-21.
15. L‘Allier P.L., Ducrocq G., Pranno N., Noble S., Ibrahim R., Grégoire J.C., Azzari F., Nozza A., Berry C., Doucet S., Labarthe B., Théroux P., Tardif J.C.; PREPAIR Study Investigators: Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study. J. Am. Coll. Cardiol. 2008 Mar 18, 51(11): 1066-72.
16. Fox K.A., Mehta S.R., Peters R., Zhao F., Lakkis N., Gersh B.J., Yusuf S.: Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-STelevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004, 110: 1202-1208.
17. Butler M.J., Eccleston D., Clark D.J., Ajani A.E., Andrianopoulos N., Brennan A., New G., Black A., Szto G., Reid C.M., Yan B.P., Shaw J.A., Dart A.M., Duffy S.J.; Melbourne Interventional Group: The Effect of Intended Duration of Clopidogrel use on Early and Late Mortality and Major Adverse Cardiac Events in Patients with Drug-eluting Stents. American Heart Journal 2009, 157(5): 899-907.
18. Mehta S.R., Bassand J.P., Chrolavicius S., Diaz R., Fox K.A.A., Granger C.B., Jolly S., Rupprecht H.J., Widimsky P., Yusuf S.: Design and rationale of CURRENT-OASIS 7: A randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non–ST-elevation acute coronary syndromes managed with an early invasive strategy. Results as presented at ESC 2009.
19. Algra A., van Gijn J.: Cumulative meta-analysis of aspirin efficacy after cerebral ischemia of arterial origin. Neurol. Neurosurg. Psychiatry 1999, 66: 255.
20. Diener H.C., Bogousslavsky J., Brass L.M., Cimminiello C., Csiba L., Kaste M., Leys D., Matias-Guiu J., Rupprecht H.J.: Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data. Cerebrovasc. Dis. 2004, 17(2-3): 253-61.
2. Katzung B.: Basic and clinical pharmacology. 10th edition. McGraw Hill, 2007.
3. von Beckerath N., Taubert D., Pogatsa-Murray G., Schomig E., Kastrati A., Schomig A.: Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 2005, 112: 2946-2950.
4. Antman E.M., Hand M., Armstrong P.W. et al.: 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. Circulation 2008, 117: 296-329.
5. Bassand J.P., Hamm C.W., Ardissino D. et al.: Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur. Heart J. 2007, 28: 1598-1660.
6. King S.B., Smith S.C., Hirshfeld J.W. et al.: 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J. Am. Coll. Cardiol. 2008, 51: 172-209.
7. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348: 1329-39.
8. Bhatt D.L., Topol E.J.; Clopidogrel for High Atherothrombotic Risk and ischemic Stabilization, Management, and Avoidance Executive Committee: Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am. Heart J. 2004 Aug, 148(2): 263-8.
9. CURE trial investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 2001, 345: 494-502.
10. Steinhubl S.R., Berger P.B., Mann J.T. III et al. (for the CREDO Investigators): Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002, 288: 2411-20.
11. Mehta S.R., Yusuf S., Peters R.J. et al.: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001, 358: 527-533.
12. Patti G., Colonna G., Pasceri V., Pepe L.L., Montinaro A., Di Sciascio G.: Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005 Apr 26, 111(16): 2099-106.
13. Sabatine M.S., Cannon C.P., Gibson C.M. et al. (for the CLARITY-TIMI 28 Investigators): Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med. 2005, 352: 1179-89.
14. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group: Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebocontrolled trial. Lancet 2005, 366: 1607-21.
15. L‘Allier P.L., Ducrocq G., Pranno N., Noble S., Ibrahim R., Grégoire J.C., Azzari F., Nozza A., Berry C., Doucet S., Labarthe B., Théroux P., Tardif J.C.; PREPAIR Study Investigators: Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study. J. Am. Coll. Cardiol. 2008 Mar 18, 51(11): 1066-72.
16. Fox K.A., Mehta S.R., Peters R., Zhao F., Lakkis N., Gersh B.J., Yusuf S.: Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-STelevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004, 110: 1202-1208.
17. Butler M.J., Eccleston D., Clark D.J., Ajani A.E., Andrianopoulos N., Brennan A., New G., Black A., Szto G., Reid C.M., Yan B.P., Shaw J.A., Dart A.M., Duffy S.J.; Melbourne Interventional Group: The Effect of Intended Duration of Clopidogrel use on Early and Late Mortality and Major Adverse Cardiac Events in Patients with Drug-eluting Stents. American Heart Journal 2009, 157(5): 899-907.
18. Mehta S.R., Bassand J.P., Chrolavicius S., Diaz R., Fox K.A.A., Granger C.B., Jolly S., Rupprecht H.J., Widimsky P., Yusuf S.: Design and rationale of CURRENT-OASIS 7: A randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non–ST-elevation acute coronary syndromes managed with an early invasive strategy. Results as presented at ESC 2009.
19. Algra A., van Gijn J.: Cumulative meta-analysis of aspirin efficacy after cerebral ischemia of arterial origin. Neurol. Neurosurg. Psychiatry 1999, 66: 255.
20. Diener H.C., Bogousslavsky J., Brass L.M., Cimminiello C., Csiba L., Kaste M., Leys D., Matias-Guiu J., Rupprecht H.J.: Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data. Cerebrovasc. Dis. 2004, 17(2-3): 253-61.